GLP-1 Weight Loss in Anchorage: The City That Matches Its State Exactly, and Carries the Whole State's Specialists
Anchorage's exact match to the Alaska obesity rate, a Medicaid-eligible-population HPSA inside a city with no general shortage, Belle Medical's published price ladder, and the PDL's missing weight-loss brands.
Anchorage's adult obesity prevalence is 35.2% (CDC PLACES 2025 release, BRFSS 2023) 1, exactly Alaska's statewide rate of 35.2% for the same survey year 2. The city is not an outlier against its state; it is its state.
It is also where the state's care is: 288,976 residents inside a 407,213-person metro, a median household income of $105,356, and a 9.4% uninsured rate derived from ACS 2024 coverage tables 34567.
County
Anchorage Municipality (unified home-rule city-borough — no separate county exists; municipality and borough are the same legal entity, FIPS 02-020)
No whole-population Primary Care HPSA covers Anchorage — HRSA has never designated the general population here as underserved. But HRSA does designate the entire borough's Medicaid-eligible population as a Primary Care HPSA (ID 1029282373, score 11, designated 4/7/2020): 94,852 Medicaid-eligible residents, an estimated 31,304 of them underserved, at a 4,478:1 population-to-provider ratio against a 3,000:1 goal (21.18 additional FTE providers needed to close the gap). About 13 facility-level Primary Care HPSAs also sit inside Anchorage, including the Alaska Native Medical Center/Southcentral Foundation tribal-health network, two FQHCs, and two correctional facilities.8
Specialist access
Anchorage is Alaska's de facto specialist hub — most of the state has no endocrinologist at all, so rural and remote Alaskans already travel here for the kind of care a GLP-1 prescription needs. The bench is still thin, and directories disagree sharply: Healthgrades lists 6 endocrinology/diabetes/metabolism specialists in Anchorage; WebMD lists 27, likely counting retired providers or duplicate listings. A realistic estimate lands in the single-to-low-double digits for a metro of about 407,000 people. HRSA doesn't track an endocrinology-specific shortage designation, so this is directory signal, not a federal designation.1112
Medicaid coverage note
Alaska expanded Medicaid under the ACA on 9/1/2015 (confirmed via KFF's state Medicaid expansion tracker). Alaska's Preferred Drug List, effective 6/1/2026 (47-page formulary, fetched and parsed directly), lists diabetes-indicated semaglutide — Ozempic and Rybelsus — as preferred/covered, and diabetes-indicated tirzepatide — Mounjaro — as non-preferred, requiring prior authorization/step therapy. Wegovy, Zepbound, and Saxenda — the weight-loss-labeled brand versions — do not appear anywhere in the PDL, meaning Alaska Medicaid's formulary process does not cover the anti-obesity indication at all. This sits on top of the HRSA finding that Anchorage's own Medicaid-eligible population (94,852 people) is a designated Primary Care shortage population within the city.10
Alaska Medicaid's formulary has no weight-loss GLP-1 on it
Alaska expanded Medicaid under the ACA on 9/1/2015. Its Preferred Drug List effective 6/1/2026, a 47-page formulary fetched and parsed directly, lists diabetes-indicated semaglutide, Ozempic and Rybelsus, as preferred and covered, and diabetes-indicated tirzepatide, Mounjaro, as non-preferred with prior authorization or step therapy 10.
Wegovy, Zepbound, and Saxenda, the weight-loss-labeled brands, do not appear anywhere in the PDL, meaning Alaska Medicaid's formulary process does not cover the anti-obesity indication at all 10. That sits on top of HRSA's finding that Anchorage's own Medicaid-eligible population, 94,852 people, is a designated primary care shortage population inside the city 8.
What GLP-1 care costs in Anchorage today
Belle Medical, an APRN-led medical spa at 2600 Denali St Suite 101, publishes a full self-pay price sheet, confirmed verbatim against the live page on 8/28/2026 9. Compounded semaglutide microdosing runs $500 per three-month supply, about $167 per month, up to 0.75mg weekly. Brand-name Wegovy runs $199/month for the first two months, then $349/month. Oral semaglutide runs $149/month at 1.5 to 4mg up to $299/month at 9 to 25mg.
Compounded tirzepatide runs $1,300 per three-month supply for new patients starting at 5mg weekly, and $600 at 5mg, $850 at 10mg, or $1,100 at 15mg per three-month supply for existing patients, roughly $200 to $433 per month, with microdosing at $600 per three-month supply. Zepbound starts at $299/month and oral Foundayo at $149/month. All of those exclude visit fees and are self-pay only 9.
Astra's national price is $68/month for semaglutide and $118/month for tirzepatide on 12-month plans, $816 and $1,416 billed annually. That price is identical in every state Astra serves; there is no city rate.
A shortage designation aimed at Medicaid-eligible residents, inside the state's specialist hub
No whole-population Primary Care HPSA covers Anchorage; HRSA has never designated the general population here as underserved. It does designate the entire borough's Medicaid-eligible population as a Primary Care HPSA, ID 1029282373, score 11, designated 4/7/2020: 94,852 Medicaid-eligible residents, an estimated 31,304 of them underserved, at a 4,478:1 population-to-provider ratio against a 3,000:1 goal, requiring 21.18 additional FTE providers to close 8. About 13 facility-level Primary Care HPSAs also sit inside Anchorage, including the Alaska Native Medical Center and Southcentral Foundation tribal-health network, two FQHCs, and two correctional facilities 8.
Anchorage is Alaska's de facto specialist hub, since most of the state has no endocrinologist at all and rural and remote Alaskans already travel here for the kind of care a GLP-1 prescription needs. The bench is still thin and directories disagree sharply: Healthgrades lists 6 endocrinology, diabetes, and metabolism specialists in Anchorage while WebMD lists 27, likely counting retired providers or duplicates 1112. A realistic estimate lands in the single to low double digits for a metro of about 407,000. HRSA issues no endocrinology-specific designation, so this is directory signal, not a federal statistic.
Astra is licensed in all 50 states, Alaska included, so a patient in Anchorage, or one who would otherwise fly into it, sees the same published price as anyone else. See the Alaska GLP-1 overview for statewide context.
Astra treats patients in Alaska through state-licensed physicians.
Local options
Belle Medical (APRN-led medical spa, 2600 Denali St, Suite 101, Anchorage) — Publishes a full self-pay price sheet. Compounded semaglutide microdosing: $500 per 3-month supply (~$167/month, up to 0.75mg/week). Brand-name Wegovy injectable: $199/month for the first 2 months, then $349/month. Oral semaglutide: $149/month (1.5–4mg) to $299/month (9–25mg). Compounded tirzepatide: $1,300 per 3-month supply for new patients (from 5mg/week); $600 (5mg), $850 (10mg), or $1,100 (15mg) per 3-month supply for existing patients (~$200–$433/month); microdosing $600 per 3-month supply. Zepbound injectable from $299/month; oral Foundayo from $149/month. All prices exclude visit fees; self-pay only. Confirmed verbatim against the live pricing page on 8/28/2026. https://www.bellemedicalak.com/pricing(checked 2026-08-28)
Frequently asked questions
How much does semaglutide or tirzepatide cost at a weight-loss clinic in Anchorage, AK?
The only Anchorage clinic with a fully published self-pay price sheet, Belle Medical, lists compounded semaglutide microdosing at about $167/month ($500 per 3-month supply), brand-name Wegovy at $199/month for the first two months then $349/month, and compounded tirzepatide at $200–$433/month depending on dose and patient status (checked 8/28/2026).
Is Anchorage's adult obesity rate different from the rest of Alaska?
No. CDC PLACES puts Anchorage's adult obesity prevalence at 35.2% (2023 BRFSS small-area estimate) — an exact match to Alaska's statewide rate of 35.2% from the same year's direct BRFSS survey. That kind of exact match is unusual for a state's largest, most urbanized city.
How many endocrinologists or obesity-medicine specialists practice in Anchorage?
Directories disagree: Healthgrades lists 6 endocrinology/diabetes/metabolism specialists in Anchorage; WebMD lists 27, likely counting retired providers or duplicate listings. Either way, Anchorage holds nearly all of Alaska's specialist capacity — most of the state has none, so rural residents already travel to Anchorage for this kind of care.
Does Alaska Medicaid cover Wegovy, Zepbound, Ozempic, or Mounjaro?
Partially, and only for diabetes. Alaska's Preferred Drug List (effective 6/1/2026) lists Ozempic and Rybelsus (semaglutide) as preferred and Mounjaro (tirzepatide) as non-preferred, requiring prior authorization. Wegovy, Zepbound, and Saxenda — the weight-loss-labeled versions — don't appear on the PDL at all, so Medicaid's process doesn't cover the anti-obesity indication.
Is Astra cheaper in Anchorage?
Based on the only Anchorage clinic with fully published pricing — Belle Medical — yes, on every listed tier. Astra's flat national rate is $68/month for semaglutide and $118/month for tirzepatide on a 12-month plan ($816/$1,416 billed annually), below Belle Medical's compounded semaglutide ($167+/month), brand-name Wegovy ($199–$349/month), compounded tirzepatide ($200–$433/month), and brand-name Zepbound (from $299/month). Astra's price doesn't change from city to city or state to state.